Axovant Sciences (AXON) Sinks as Lundbeck 5-HT6 antagonist Fails

September 22, 2016 12:11 PM EDT
Get Alerts AXON Hot Sheet
Trade AXON Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Axovant Sciences (NYSE: AXON) weakens on news Lundbeck 5-HT6 antagonist fails in Alzheimer's Phase III. Adam Feuerstein notes on Twitter that AXON also has a 5-HT6 antagonist.





Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Related Entities

Twitter, Adam Feuerstein

Add Your Comment